What Is FOXO4-DRI? A Retro-Inverso Senolytic Peptide

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

FOXO4-DRI is one of the few peptides in a research catalogue whose name encodes its chemistry rather than its origin or its claimed effect. Understanding the “DRI” is most of understanding the molecule, and it has an analytical consequence that catches people out: a DRI peptide has exactly the same mass as the L-peptide it was built from.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

What D-retro-inverso means

The construction has two steps applied together:

Reverse the sequence. Read the parent peptide’s residues from C-terminus to N-terminus.
Switch every residue to the D enantiomer.

Done together, these two inversions largely cancel at the level of side-chain geometry. The backbone direction is reversed and the stereochemistry is inverted, with the result that the side chains end up in approximately the spatial arrangement they occupied in the parent. The molecule can therefore present a similar surface to a binding partner while being built from bonds that L-specific proteases do not recognise.

Property	L-parent peptide	DRI version
Amino acid composition	Same residues	Same residues
Molecular formula	Identical	Identical
Molecular mass	Identical	Identical
Sequence order	N to C	Reversed
Stereochemistry	L	D
Protease susceptibility	Normal	Strongly reduced
Chromatographic retention	Differs	Differs

The mass rows are the practical warning. Mass spectrometry cannot confirm that a vial contains the DRI peptide rather than the L-peptide of the same composition. Only chromatographic behaviour, or an explicit chiral analysis, distinguishes them. A certificate reporting an expected mass and nothing else has not established which molecule is present. See how to read a certificate of analysis.

The target, as of 2025

The 2025 paper by Bourgeois and colleagues in Nature Communications is the key mechanistic reference, and its title states the finding: the disordered p53 transactivation domain is the target of both FOXO4 and the FOXO4-DRI compound.

Two things make that an unusually satisfying result for a compound of this type. First, it identifies the binding site rather than inferring the pathway from downstream readouts — which is more than can be said for many research peptides. Second, the target is an intrinsically disordered region, which explains why a flexible peptide is a plausible ligand for it: disordered regions are poor targets for rigid small molecules and relatively good ones for peptides.

The proposed logic of the compound follows from this. If FOXO4 binds p53 and holds it where it cannot act, a competitor for that interaction releases p53. The 2025 study by Kong and colleagues in Communications Biology reports exactly that kind of downstream observation, describing nuclear exclusion of phosphorylated p53 in keloid senescent fibroblasts.

Where the class is being studied

Study	Year	System	Contribution
Bourgeois, Nat Commun	2025	Structural / biophysical	Identifies the binding site
Kong, Commun Biol	2025	Keloid fibroblasts	Downstream p53 localisation
Alameen, Naunyn Schmiedebergs	2026	Brain aging, review	Places retro-inverso senolytics as a class
Born, Circulation	2023	Pulmonary hypertension	Senolysis worsened outcomes

The result that should be read alongside the others

The 2023 Circulation study by Born and colleagues is the one we would put in front of anyone planning a senolytic experiment. It reported that eliminating senescent cells promoted pulmonary hypertension development and progression in its model.

This matters because the framing around senolytics tends to assume that removing senescent cells is desirable by definition. That assumption is an empirical claim, and in at least one well-conducted study in a major journal it did not hold. Senescent cells have functions; removing them changes a system in more than one direction.

For experimental design, the implication is concrete: a senolytic experiment needs a readout capable of detecting harm, not only one capable of detecting benefit. An assay that measures only the hoped-for direction cannot distinguish a compound that works from one that does something else as well.

Handling

The D-residue content changes the handling profile favourably in one respect and complicates it in another.

Proteolytic stability is high. This is the point of the design, and it means the peptide survives in protease-containing media far better than an L-peptide of the same sequence.
Chemical degradation routes are unchanged. D-amino acids resist proteases, not oxidation or deamidation. Light protection and a low-metal diluent still apply.
Identity cannot be confirmed by mass alone, as above. Request the chromatogram and, where the work depends on it, ask whether chiral analysis was performed.
Store sealed, dry and dark at −20 °C; aliquot on first reconstitution. See lyophilized peptide storage.
Compute molarity from net peptide content. Our reconstitution calculator takes molecular weight and net mass from the certificate.

Our FOXO4-DRI research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report. For a retro-inverso peptide this is one of the cases where reading the stated sequence carefully — direction and stereochemistry both — is worth the two minutes it takes.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. The work described above is structural, cell-based and animal research.

Open questions

In which tissues does senescent cell elimination produce harm rather than benefit?
How selective is the FOXO4–p53 disruption against other p53 interactions?
Can the DRI form be distinguished from its L-parent by a routine release test?

Frequently asked questions

What does DRI stand for?

D-retro-inverso. The peptide is built from D-amino acids in reverse sequence order, which produces a molecule whose side chains occupy approximately the same spatial arrangement as the original L-peptide while being resistant to proteases that act on L-peptide bonds.

What does FOXO4-DRI target?

The interaction between FOXO4 and p53. A 2025 Nature Communications study identified the disordered p53 transactivation domain as the binding site for both FOXO4 and the FOXO4-DRI compound, which is the most direct mechanistic evidence available.

What is a senolytic?

A compound intended to selectively eliminate senescent cells, which are cells that have exited division but remain metabolically active. FOXO4-DRI belongs to this class and its proposed mechanism works by releasing p53 from sequestration.

Is a retro-inverso peptide identical in mass to the parent?

Yes, which is an important analytical point. Reversing the sequence and switching to D-amino acids changes neither the composition nor the molecular formula, so mass spectrometry alone cannot distinguish a DRI peptide from its L-peptide parent. Chromatography is what resolves it.

Is eliminating senescent cells always beneficial?

No, and the literature says so. A 2023 Circulation study reported that eliminating senescent cells promoted pulmonary hypertension development and progression in its model. That is a reason to treat senolytic experiments as context-dependent rather than uniformly positive.

References

Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025. PMID: 40593617 https://pubmed.ncbi.nlm.nih.gov/40593617/
Kong YX, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025. PMID: 39994346 https://pubmed.ncbi.nlm.nih.gov/39994346/
Alameen AAM, et al. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 42024235 https://pubmed.ncbi.nlm.nih.gov/42024235/
Born E, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023. PMID: 36515093 https://pubmed.ncbi.nlm.nih.gov/36515093/